Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1143 | 1027 | 1174 | 1160 | 1362 | 2079 |
Fund Return | 14.35% | 2.69% | 17.44% | 5.09% | 6.38% | 7.59% |
Place in category | 40 | 228 | 75 | 16 | 112 | 29 |
% in Category | 7 | 32 | 13 | 4 | 25 | 9 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 9.66B | 21.91 | 7.35 | 11.88 | ||
UBS CH Vitainvest 50 World U | 4.38B | 2.45 | -0.62 | 2.66 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.41B | 20.41 | 4.96 | 9.21 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.92B | 11.68 | -0.82 | 6.98 | ||
UBS CH Institutional Fund 2 EquiSCB | 2.92B | 11.63 | -0.87 | 6.92 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.34B | 9.28 | 2.17 | 6.28 | ||
Raiffeisen Futura Swiss Stock A | 2.15B | 7.92 | -0.59 | 6.39 | ||
UBS CH Equity Fund Swiss Income CHF | 2.04B | 2.43 | 3.56 | 5.81 | ||
UBS CH Equity Fund Swiss Income CHQ | 2.04B | 2.59 | 4.20 | 6.41 | ||
Pictet CH Institutional Swiss EquiZ | 1.72B | 11.68 | 1.93 | 7.71 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novartis | CH0012005267 | 9.89 | 92.73 | +0.85% | |
Roche Holding Participation | CH0012032048 | 9.85 | 261.60 | -0.57% | |
Nestle | CH0038863350 | 9.52 | 78.74 | +1.31% | |
UBS Group | CH0244767585 | 8.01 | 28.28 | +0.75% | |
Zurich Insurance Group | CH0011075394 | 7.59 | 526.40 | +1.19% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Neutral | Buy |
Technical Indicators | Strong Sell | Sell | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review